Questcor is Now a Part of Mallinckrodt
Acthar Customer Service
Acthar Patient Reimbursement& Support Services
Autoimmune & Rare Diseases Careers
Grants & Fellowships
Research & Development
Sunshine Act Dispute Form
Mallinckrodt is pleased to bring Questcor and its entire business into our company, including its main product, H.P. Acthar® Gel (repository corticotropin injection), a naturally-derived formulation of adrenocorticotropic hormones used in a variety of disorders having an inflammatory component.
The former Questcor organization will be known as the Autoimmune and Rare Diseases business within Mallinckrodt’s Specialty Pharmaceuticals segment. We will continue their focus on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders, primarily in the fields of neurology, nephrology, rheumatology and pulmonology. All are areas of medicine which have significant unmet medical needs.
H.P. Acthar® Gel is now
part of the Mallinckrodt Pharmaceuticals portfolio of products. Please click here for Full Prescribing Information for H.P. Acthar Gel. To learn more
about Acthar and it's FDA-approved therapeutic indications, visit www.acthar.com.
Mallinckrodt, the 'M' brand mark, the Mallinckrodt Pharmaceuticals logo and other brands are trademarks of a Mallinckrodt company. © 2014 Mallinckrodt.
Mallinckrodt Pharmaceuticals is a registered business name of Mallinckrodt plc, which is registered in Ireland as a public limited company with registration number 522227 and has its registered office at Damastown, Mulhuddart, Dublin 15, Ireland.